scholarly journals Matching Adjusted Indirect Comparison (MAIC) Analysis For Ponatinib Vs Bosutinib In Third-Line Chronic Phase Chronic Myeloid Leukemia (CP-CML)

2016 ◽  
Vol 19 (7) ◽  
pp. A577
Author(s):  
S Iannazzo ◽  
L McGarry ◽  
S Lustgarten ◽  
S Chiroli
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Indirect Comparison ◽  
Chronic Phase ◽  
Adjusted Indirect Comparison ◽  
Third Line

One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 7072-7072
Author(s):  
James E. Signorovitch ◽  
Eric Qiong Wu ◽  
Keith A. Betts ◽  
William M. Reichmann ◽  
Darren Thomason ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Indirect Comparison ◽  
Newly Diagnosed ◽  
Molecular Responses ◽  
Adjusted Indirect Comparison ◽  
One Year

scholarly journals An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia

2021 ◽  
pp. 1-9
Author(s):  
Bogdan Muresan ◽  
Carla Mamolo ◽  
Joseph C. Cappelleri ◽  
Eric Leip ◽  
Andrea Viqueira ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Indirect Comparison ◽  
Chronic Phase ◽  
First Line

scholarly journals Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Blood ◽  
2010 ◽  
Vol 116 (25) ◽  
pp. 5497-5500 ◽  
Author(s):  
Amr R. Ibrahim ◽  
Christos Paliompeis ◽  
Marco Bua ◽  
Dragana Milojkovic ◽  
Richard Szydlo ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Chronic Phase ◽  
Cytogenetic Response ◽  
Second Line ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

Abstract We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors for the achievement of complete cytogenetic responses on third-line therapy. Younger age and the achievement of a cytogenetic response on second line were the only independent predictors for overall survival (OS). At 3 months, the 9 patients who had achieved a cytogenetic response had better 30-month probabilities of complete cytogenetic responses and OS than the patients who had failed to do so. Factors measurable before starting treatment with third line therapy and cytogenetic responses at 3 months can accurately predict subsequent outcome and thus guide clinical decisions.

Sign in / Sign up

Export Citation Format

Share Document